<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ALOPRIM- allopurinolÂ injection, powder, lyophilized, for solutionÂ </strong><br>Mylan Institutional LLC<br></p></div>
<h1><span class="Bold">ALOPRIM<span class="Sup">Â®</span> (allopurinol sodium) for Injection</span></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c2c58844-1a80-4251-8cc1-ef415d5f1183"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">500 mg</span></p>
<p>[<span class="Italics">al'-Å?-prÄ­m</span>]</p>
<p><span class="Bold">For Intravenous Infusion Only</span></p>
<p><span class="Bold">PRODUCT INFORMATION</span></p>
<p><span class="Bold">013401</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_3bc68aed-5609-4ee0-b91a-b4dbad36977f"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">ALOPRIM (allopurinol sodium) for Injection is the brand name for allopurinol, a xanthine oxidase inhibitor. ALOPRIM (allopurinol sodium) for Injection is a sterile solution for intravenous infusion only. It is available in vials as the sterile lyophilized sodium salt of allopurinol equivalent to 500 mg of allopurinol. ALOPRIM (allopurinol sodium) for Injection contains no preservatives.</p>
<p>The chemical name for allopurinol sodium is 1,5-dihydro-4<span class="Italics">H</span>-pyrazolo[3,4-<span class="Italics">d</span>]pyrimidin-4-one monosodium salt. It is a white amorphous <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> with a molecular weight of 158.09 and molecular formula C<span class="Sub">5</span>H<span class="Sub">3</span>N<span class="Sub">4</span>NaO. The structural formula is:</p>
<div class="Figure">
<a name="id231"></a><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=10cc918f-aa44-415b-932d-2404695ac449&amp;name=084bfc21-a46e-45e5-925d-aaa806351658-01.jpg">
</div>
<p>The pKa of allopurinol sodium is 9.31.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_9e08e9a2-3833-4e0a-969e-ddf342a43961"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Allopurinol acts on purine catabolism without disrupting the biosynthesis of purines. It reduces the production of uric acid by inhibiting the biochemical reactions immediately preceding its formation. The degree of this decrease is dose dependent.</p>
<p>Allopurinol is a structural analogue of the natural purine base, hypoxanthine. It is an inhibitor of xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine and of xanthine to uric acid, the end product of purine metabolism in man. Allopurinol is metabolized to the corresponding xanthine analogue, oxypurinol (alloxanthine), which also is an inhibitor of xanthine oxidase.</p>
<p>Reutilization of both hypoxanthine and xanthine for nucleotide and nucleic acid synthesis is markedly enhanced when their oxidations are inhibited by allopurinol and oxypurinol. This reutilization does not disrupt normal nucleic acid anabolism, however, because feedback inhibition is an integral part of purine biosynthesis. As a result of xanthine oxidase inhibition, the serum concentration of hypoxanthine plus xanthine in patients receiving allopurinol for treatment of <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span> is usually in the range of 0.3 to 0.4 mg/dL compared to a normal level of approximately 0.15 mg/dL. A maximum of 0.9 mg/dL of these oxypurines has been reported when the serum urate was lowered to less than 2 mg/dL by high doses of allopurinol. These values are far below the saturation levels, at which point their precipitation would be expected to occur (above 7 mg/dL).</p>
<p>The renal clearance of hypoxanthine and xanthine is at least 10 times greater than that of uric acid. The increased xanthine and hypoxanthine in the urine have not been accompanied by problems of <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">nephrolithiasis</span>. There are isolated case reports of xanthine <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span> in patients who were treated with oral allopurinol.</p>
<p>The action of oral allopurinol differs from that of uricosuric agents, which lower the serum uric acid level by increasing urinary excretion of uric acid. Allopurinol reduces both the serum and urinary uric acid levels by inhibiting the formation of uric acid. The use of allopurinol to block the formation of urates avoids the hazard of increased renal excretion of uric acid posed by uricosuric drugs.</p>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_9240bc82-1762-4ff5-9366-cf8b43b7e4b0"></a><a name="section-3.1"></a><p></p>
<h2>PHARMACOKINETICS</h2>
<p class="First">Following intravenous administration in six healthy male and female subjects, allopurinol was rapidly eliminated from the systemic circulation primarily via oxidative metabolism to oxypurinol, with no detectable plasma concentration of allopurinol after 5 hours post dosing. Approximately 12% of the allopurinol intravenous dose was excreted unchanged, 76% excreted as oxypurinol, and the remaining dose excreted as riboside conjugates in the urine. The rapid conversion of allopurinol to oxypurinol was not significantly different after repeated allopurinol dosing. Oxypurinol was present in systemic circulation in much higher concentrations and for a much longer period than allopurinol; thus, it is generally believed that the pharmacological action of allopurinol is mediated via oxypurinol. Oxypurinol was primarily eliminated unchanged in urine by glomerular filtration and tubular reabsorption, with a net renal clearance of about 30 mL/min.</p>
<p>To compare the pharmacokinetics of allopurinol and oxypurinol between intravenous (i.v.) and oral (p.o.) administration of ALOPRIM (allopurinol sodium) for Injection, a well-controlled, four-way crossover study was conducted in 16 male healthy volunteers. ALOPRIM (allopurinol sodium) for Injection was administered via an intravenous infusion over 30 minutes. Pharmacokinetic parameter estimates of allopurinol (mean Â± S.D.) following single i.v. and p.o. administration of ALOPRIM (allopurinol sodium) for Injection are summarized as follows:</p>
<a name="_Refid_557780a6-1641-40dd-b820-38a72b5b7"></a><table width="100%">
<caption><span>Administration of ALOPRIM<span class="Sup">Â®</span> (allopurinol sodium) for Injection</span></caption>
<col width="26%">
<col width="13%">
<col width="13%">
<col width="14%">
<col width="14%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Allopurinol Parameters</span></th>
<th class="Botrule Rrule Toprule" align="left" valign="top"><span class="Bold">100 mg i.v.</span></th>
<th class="Botrule Rrule Toprule" align="left" valign="top"><span class="Bold">300 mg i.v.</span></th>
<th class="Botrule Rrule Toprule" align="left" valign="top">
<span class="Bold">100 mg p.o.</span><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</th>
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">300 mg p.o.</span></th>
</tr></thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>n=7</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">â€ </a></dt>
<dd>Volume of Distribution (Steady-State)</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">â€¡</a></dt>
<dd>Absolute Bioavailability</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Toprule"><p class="First">C<span class="Sub">max</span> (Âµg/mL)</p></td>
<td class="Toprule"><p class="First">1.58 Â± 0.22</p></td>
<td class="Toprule"><p class="First">5.12 Â± 0.82</p></td>
<td class="Toprule"><p class="First">0.53 Â± 0.10</p></td>
<td class="Rrule Toprule"><p class="First">1.35 Â± 0.49</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First">T<span class="Sub">max</span> (hr)</p></td>
<td><p class="First">0.50</p></td>
<td><p class="First">0.50</p></td>
<td><p class="First">1.00 Â± 0.39</p></td>
<td class="Rrule"><p class="First">1.67 Â± 0.96</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First">T 1/2 (hr)</p></td>
<td><p class="First">1.00 Â± 0.46</p></td>
<td><p class="First">1.21 Â± 0.33</p></td>
<td><p class="First">0.98 Â± 0.43</p></td>
<td class="Rrule"><p class="First">1.32 Â± 0.32</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First">AUC<span class="Sub">0 -&gt;âˆž</span> (hrâˆ™Âµg/mL)</p></td>
<td><p class="First">1.99 Â± 0.63</p></td>
<td><p class="First">7.10 Â± 1.28</p></td>
<td><p class="First">1.03 Â± 0.24</p></td>
<td class="Rrule"><p class="First">3.69 Â± 0.96</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First">CL (mL/min/kg)</p></td>
<td><p class="First">12.2 Â± 3.11</p></td>
<td><p class="First">9.94 Â± 2.36</p></td>
<td></td>
<td class="Rrule"></td>
</tr>
<tr>
<td class="Lrule"><p class="First">V<span class="Sub">ss</span> (L/kg)<a name="footnote-reference-2" href="#footnote-2" class="Sup">â€ </a></p></td>
<td><p class="First">0.84 Â± 0.13</p></td>
<td><p class="First">0.87 Â± 0.13</p></td>
<td></td>
<td class="Rrule"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First">F<span class="Sub">absolute</span> (%)<a name="footnote-reference-3" href="#footnote-3" class="Sup">â€¡</a></p></td>
<td class="Botrule"></td>
<td class="Botrule"></td>
<td class="Botrule"><p class="First">48.8 Â± 19.7</p></td>
<td class="Botrule Rrule"><p class="First">52.7 Â± 13.1</p></td>
</tr>
</tbody>
</table>
<p>Oxypurinol was measurable in the plasma within 10 to 15 minutes following the administration of ALOPRIM (allopurinol sodium) for Injection. Pharmacokinetic parameter estimates of oxypurinol following i.v. and p.o. administration of ALOPRIM (allopurinol sodium) for Injection are shown below:</p>
<a name="_Refid_552c57f1-367b-4660-bbe9-0b3e714a5"></a><table width="100%">
<caption><span>Administration of ALOPRIM<span class="Sup">Â®</span> (allopurinol sodium) for Injection</span></caption>
<col width="26%">
<col width="13%">
<col width="13%">
<col width="14%">
<col width="14%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Oxypurinol Parameters</span></th>
<th class="Botrule Rrule Toprule" align="left" valign="top"><span class="Bold">100 mg i.v.</span></th>
<th class="Botrule Rrule Toprule" align="left" valign="top"><span class="Bold">300 mg i.v.</span></th>
<th class="Botrule Rrule Toprule" align="left" valign="top"><span class="Bold">100 mg p.o.</span></th>
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">300 mg p.o.</span></th>
</tr></thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>Relative Bioavailability</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Toprule"><p class="First">C<span class="Sub">max</span> (Âµg/mL)</p></td>
<td class="Toprule"><p class="First">2.20 Â± 0.31</p></td>
<td class="Toprule"><p class="First">6.18 Â± 0.78</p></td>
<td class="Toprule"><p class="First">2.36 Â± 0.30</p></td>
<td class="Rrule Toprule"><p class="First">6.36 Â± 0.83</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First">T<span class="Sub">max</span> (hr)</p></td>
<td><p class="First">3.89 Â± 1.41</p></td>
<td><p class="First">4.16 Â± 1.2</p></td>
<td><p class="First">3.10 Â± 1.49</p></td>
<td class="Rrule"><p class="First">4.13 Â± 1.35</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First">T 1/2 (hr)</p></td>
<td><p class="First">24.1 Â± 5.4</p></td>
<td><p class="First">23.5 Â± 4.5</p></td>
<td><p class="First">24.9 Â± 8.4</p></td>
<td class="Rrule"><p class="First">23.7 Â± 3.4</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First">AUC<span class="Sub">0 -&gt;âˆž</span> (hrâˆ™Âµg/mL)</p></td>
<td><p class="First">80 Â± 24</p></td>
<td><p class="First">231 Â± 54</p></td>
<td><p class="First">83 Â± 22</p></td>
<td class="Rrule"><p class="First">245 Â± 49</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First">F<span class="Sub">relative</span> (%)<a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a></p></td>
<td class="Botrule"></td>
<td class="Botrule"></td>
<td class="Botrule"><p class="First">107 Â± 25</p></td>
<td class="Botrule Rrule"><p class="First">108 Â± 9</p></td>
</tr>
</tbody>
</table>
<p>In general, the ratio of the area under the plasma concentration vs time curve (AUC<span class="Sub">0-&gt;âˆž</span>) between oxypurinol and allopurinol was in the magnitude of 30 to 40. The C<span class="Sub">max</span> and AUC<span class="Sub">0-&gt;âˆž</span> for both allopurinol and oxypurinol following i.v. administration of ALOPRIM (allopurinol sodium) for Injection were dose proportional in the dose range of 100 to 300 mg. The half-life of allopurinol and oxypurinol was not influenced by the route of ALOPRIM (allopurinol sodium) for Injection administration. Oral and intravenous administration of ALOPRIM (allopurinol sodium) for Injection at equal doses produced nearly superimposable oxypurinol plasma concentration vs time profiles, and the relative bioavailability of oxypurinol (F<span class="Sub">relative</span>) was approximately 100%. Thus, the pharmacokinetics and plasma profiles of oxypurinol, the major pharmacological component derived from allopurinol, are similar after intravenous and oral administration of ALOPRIM (allopurinol sodium) for Injection.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0af086cb-c640-4d14-b265-ae7a44da4005"></a><a name="section-3.1.1"></a><p></p>
<h3><span class="Bold">Clinical Trials</span></h3>
<p class="First">A compassionate plea trial was conducted from 1977 through 1989 in which 718 evaluable patients with malignancies requiring treatment with cytotoxic chemotherapy, but who were unable to ingest or retain oral medication, received i.v. ALOPRIM (allopurinol sodium) for Injection in the U.S. Of these patients, 411 had established <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span> and 307 had normal serum urate levels at the time that treatment was initiated. Normal serum uric acid levels were achieved in 68% (reduction of serum uric acid was documented in 93%) of the former, and were maintained throughout chemotherapy in 97% of the latter. Because of the study design, it was not possible to assess the impact of the treatment upon the clinical outcome of the patient groups.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_ID_indications"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">ALOPRIM (allopurinol sodium) for Injection is indicated for the management of patients with <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span>, <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>, and <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumor</span> malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_8382c83d-c254-4951-b9a5-fc33978b431a"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Patients who have developed a severe reaction to allopurinol should not be restarted on the drug.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_ID_warnings"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">ALLOPURINOL SHOULD BE DISCONTINUED AT THE FIRST APPEARANCE OF <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">SKIN RASH</span> OR OTHER SIGNS WHICH MAY INDICATE AN <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">ALLERGIC REACTION</span>. In some instances with oral allopurinol, a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> may be followed by more severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> such as exfoliative, urticarial, and purpuric lesions as well as <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> (<span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme exudativum</span>), and/or generalized <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>, irreversible hepatotoxicity and, on rare occasions, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p>In patients receiving mercaptopurine or azathioprine, the concomitant administration of 300 to 600 mg of ALOPRIM (allopurinol sodium) for Injection per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine. Subsequent adjustment of doses of mercaptopurine or azathioprine should be made on the basis of therapeutic response and the appearance of toxic effects (see <a href="#i4i_interactions_id_3c206d32-e8ec-46cf-843f-e829fe87839b">PRECAUTIONS: Drug Interactions</a>).</p>
<p>A few cases of reversible clinical hepatotoxicity have been noted in patients taking oral allopurinol, and in some patients asymptomatic rises in serum alkaline phosphatase or serum transaminase have been observed. If <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, or <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> develop in patients on allopurinol, evaluation of liver function should be part of their diagnostic workup. In patients with pre-existing liver disease, periodic liver function tests are recommended during the early stages of therapy.</p>
<p>Due to the occasional occurrence of <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, patients should be alerted to the need for due precaution when engaging in activities where alertness is mandatory.</p>
<p>The occurrence of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> to allopurinol may be increased in patients with decreased renal function receiving thiazides and allopurinol concurrently. Thus, in patients with decreased renal function, such combinations should be administered with caution.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_f68d6b62-a6f3-4c3a-a4d2-cda3b173e894"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_8947c4c9-67fb-4cff-95a4-a301a2ed6dc9"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">A fluid intake sufficient to yield a daily urinary output of at least two liters in adults and the maintenance of a neutral or, preferably, slightly alkaline urine are desirable to (1) avoid the theoretical possibility of formation of xanthine calculi under the influence of allopurinol therapy and (2) help prevent renal precipitation of urates in patients receiving concomitant uricosuric agents.</p>
<p>A few patients with pre-existing <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> or poor urate clearance have shown a rise in BUN during allopurinol administration, although a decrease in BUN has also been observed. In patients with <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span> due to malignancy, the vast majority of changes in renal function are attributable to the underlying malignancy rather than to therapy with allopurinol. Concurrent conditions such as <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span> and congestive myocardial disease were present among those patients whose renal function deteriorated after allopurinol was begun. <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal failure</span> is rarely associated with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> to allopurinol.</p>
<p>Patients with decreased renal function do require lower doses of allopurinol. Patients should be carefully observed during the early stages of allopurinol administration so that the dosage can be appropriately adjusted for renal function.</p>
<p>In patients with severely <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> or decreased urate clearance, the half-life of oxypurinol in the plasma is greatly prolonged. Patients should be treated with the lowest effective dose, in order to minimize possible side effects. The appropriate dose of ALOPRIM (allopurinol sodium) for Injection for patients with a creatinine clearance â‰¤10 mL/min is 100 mg per day. For patients with a creatinine clearance between 10 and 20 mL/min, a dose of 200 mg per day is recommended. With extreme <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance less than 3 mL/min), the interval between doses may also need to be extended.</p>
<p>Bone marrow suppression has been reported in patients receiving allopurinol; however, most of these patients were receiving concomitant medications with the known potential to cause such an effect. The suppression has occurred from as early as 6 weeks to as long as 6 years after the initiation of allopurinol therapy.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_id_b0b4311d-3ef2-499a-a2ab-bd096575363f"></a><a name="section-7.2"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">The correct dosage and schedule for maintaining the serum uric acid within the normal range is best determined by using the serum uric acid as an index.</p>
<p>In patients with pre-existing liver disease, periodic liver function tests are recommended during the early stages of therapy (see <a href="#i4i_warnings_ID_warnings">WARNINGS</a>).</p>
<p>Allopurinol and its primary active metabolite, oxypurinol, are eliminated by the kidneys; therefore, changes in renal function have a profound effect on dosage. In patients with decreased renal function, or who have concurrent illnesses which can affect renal function such as <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, periodic laboratory parameters of renal function, particularly BUN and serum creatinine or creatinine clearance, should be performed and the patient's allopurinol dosage reassessed.</p>
<p>The <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time should be reassessed periodically in the patients receiving dicumarol who are given allopurinol.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_3c206d32-e8ec-46cf-843f-e829fe87839b"></a><a name="section-7.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">The following drug interactions were observed in some patients undergoing treatment with oral allopurinol. Although the pattern of use for oral allopurinol includes longer term therapy, particularly for <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span> and <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">renal calculi</span>, the experience gained may be relevant.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_af759228-e25b-4e53-8033-bd1cd6857a14"></a><a name="section-7.3.1"></a><p></p>
<h3><span class="Bold">Mercaptopurine/Azathioprine</span></h3>
<p class="First">Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric acid. This oxidation, which is catalyzed by xanthine oxidase, inactivates mercaptopurine. Therefore, the concomitant administration of 300 to 600 mg of oral allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine. Subsequent adjustment of doses of mercaptopurine or azathioprine should be made on the basis of therapeutic response and the appearance of toxic effects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a4c35122-d0fd-4ffa-82c2-9fc4fb151ec1"></a><a name="section-7.3.2"></a><p></p>
<h3><span class="Bold">Dicumarol</span></h3>
<p class="First">It has been reported that allopurinol prolongs the half-life of the anticoagulant, dicumarol. Consequently, <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time should be reassessed periodically in patients receiving both drugs. The clinical basis of this drug interaction has not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d1f84aea-f25b-4c04-b214-9d559672cacf"></a><a name="section-7.3.3"></a><p></p>
<h3><span class="Bold">Uricosuric Agents</span></h3>
<p class="First">Since the excretion of oxypurinol is similar to that of urate, uricosuric agents, which increase the excretion of urate, are also likely to increase the excretion of oxypurinol. As a result, the concomitant administration of uricosuric agents decreases the inhibition of xanthine oxidase by oxypurinol and increases the urinary excretion of uric acid.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2fd2798c-216c-4d51-a920-1d78fde7aeae"></a><a name="section-7.3.4"></a><p></p>
<h3><span class="Bold">Thiazide Diuretics</span></h3>
<p class="First">Reports that the concomitant administration of allopurinol and thiazide diuretics contributed to increased allopurinol toxicity were reviewed; a causal mechanism or cause-and-effect relationship was not found. Renal function should be monitored in patients on thiazide diuretics and allopurinol (see <a href="#i4i_warnings_ID_warnings">WARNINGS</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4f2a56f7-5264-410b-8f74-64850392f702"></a><a name="section-7.3.5"></a><p></p>
<h3><span class="Bold">Ampicillin/Amoxicillin</span></h3>
<p class="First">An increase in the frequency of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs. The cause of this reaction has not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d84d8c4c-8292-4d5a-9544-f5a798f2f7f0"></a><a name="section-7.3.6"></a><p></p>
<h3><span class="Bold">Cytotoxic Agents</span></h3>
<p class="First">Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease, except <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span>, in the presence of allopurinol. However, in a well-controlled study of patients with <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> on combination therapy, allopurinol did not increase the marrow toxicity of patients treated with cyclophosphamide, doxorubicin, bleomycin, procarbazine, and/or mechlorethamine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_34802178-80ca-44c7-9356-0744b7f1e940"></a><a name="section-7.3.7"></a><p></p>
<h3><span class="Bold">Chlorpropamide</span></h3>
<p class="First">The half-life of chlorpropamide in the plasma may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule. The risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> secondary to this mechanism may be increased if allopurinol and chlorpropamide are given concomitantly in the presence of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c4490d2b-c19d-492d-8fbd-78d41f81cc20"></a><a name="section-7.3.8"></a><p></p>
<h3><span class="Bold">Cyclosporine</span></h3>
<p class="First">Reports indicate that cyclosporine levels may be increased during concomitant treatment with ALOPRIM (allopurinol sodium) for Injection. Monitoring of cyclosporine levels and possible adjustment of cyclosporine dosage should be considered when these drugs are co-administered.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="i4i_drug_lab_interaction_id_545af786-dbc6-4bc6-82e3-a6f0b8eb3d24"></a><a name="section-7.3.9"></a><p></p>
<h3><span class="Bold">Drug/Laboratory Test Interactions</span></h3>
<p class="First">Allopurinol is not known to alter the accuracy of laboratory tests.</p>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_bbae3bb0-18f9-440c-8185-506b3dd71e4c"></a><a name="section-7.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis and Impairment of Fertility</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3958a7dc-48e9-4bac-babc-c415b0be7357"></a><a name="section-7.4.1"></a><p></p>
<h3><span class="Bold">Carcinogenesis</span></h3>
<p class="First">Allopurinol was administered at doses up to 20 mg/kg/day to mice and rats for the majority of their life span. No evidence of carcinogenicity was seen in either mice or rats (at doses about 1/6 or 1/3 the recommended human dose on a mg/m<span class="Sup">2</span> basis, respectively).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0750128c-b60e-46f8-9d86-a28da1f4a888"></a><a name="section-7.4.2"></a><p></p>
<h3><span class="Bold">Mutagenesis</span></h3>
<p class="First">Allopurinol administered intravenously to rats (50 mg/kg) was not incorporated into rapidly replicating intestinal DNA. No evidence of clastogenicity was observed in an in vivo micronucleus test in rats, or in <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> taken from patients treated with allopurinol (mean duration of treatment 40 months), or in an in vitro assay with human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e044357f-68e3-4682-9d7f-b1b013f5a241"></a><a name="section-7.4.3"></a><p></p>
<h3><span class="Bold">Impairment of Fertility</span></h3>
<p class="First">Allopurinol oral doses of 20 mg/kg/day had no effect on male or female fertility in rats or rabbits (about 1/3 or 1/2 the human dose on a mg/m<span class="Sup">2</span> basis, respectively).</p>
</div>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_942cee0b-78eb-4bbc-a63e-70094d82a89f"></a><a name="section-7.5"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_b992b3a1-2b38-4e45-a0d7-674daf44c0c1"></a><a name="section-7.5.1"></a><p></p>
<h3><span class="Bold">Teratogenic Effects</span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_09625a28-1f04-45e7-a083-b3dbeef9fa59"></a><a name="section-7.5.1.1"></a><p></p>
<h4><span class="Bold">Pregnancy Category C</span></h4>
<p class="First">There was no evidence of fetotoxicity or <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> in rats or rabbits treated during the period of organogenesis with oral allopurinol at doses up to 200 mg/kg/day and up to 100 mg/kg/day, respectively (about three times the human dose on a mg/m<span class="Sup">2</span> basis). However, there is a published report in pregnant mice that single intraperitoneal doses of 50 or 100 mg/kg (about 1/3 or 3/4 the human dose on a mg/m<span class="Sup">2</span> basis) of allopurinol on gestation days 10 or 13 produced significant increases in <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal deaths</span> and teratogenic effects (<span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span>, harelip, and digital defects). It is uncertain whether these findings represented a fetal effect or an effect secondary to maternal toxicity. There are, however, no adequate or well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p>Experience with allopurinol during human pregnancy has been limited partly because women of reproductive age rarely require treatment with allopurinol. Two unpublished reports and one published paper describe women giving birth to normal offspring after receiving oral allopurinol during pregnancy. There have been no pregnancies reported in patients receiving ALOPRIM (allopurinol sodium) for Injection, but it is assumed that the same risks would apply.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_53268bb5-e602-446f-af0a-e36c26e0e811"></a><a name="section-7.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Allopurinol and oxypurinol have been found in the milk of a mother who was receiving allopurinol. Since the effect of allopurinol on the nursing infant is unknown, caution should be exercised when allopurinol is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_6c4fdfcb-1ef5-4863-b4e5-98ee92df6d64"></a><a name="section-7.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Clinical data are available on approximately 200 pediatric patients treated with ALOPRIM (allopurinol sodium) for Injection. The efficacy and safety profile observed in this patient population were similar to that observed in adults (see <a href="#i4i_indications_ID_indications">INDICATIONS</a> and <a href="#i4i_dosage_admin_ID_da">DOSAGE AND ADMINISTRATION</a>).</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_ba7c8d20-9d33-43a5-bf5d-8b516fc13aa6"></a><a name="section-7.8"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of ALOPRIM (allopurinol sodium) for Injection did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently than younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_0e69ba20-cbb1-48b4-a6cc-9253844e0f5b"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">In an uncontrolled, compassionate plea protocol, 125 of 1,378 patients reported a total of 301 adverse reactions while receiving ALOPRIM (allopurinol sodium) for Injection. Most of the patients had advanced malignancies or serious underlying diseases and were taking multiple concomitant medications. Side effects directly attributable to ALOPRIM (allopurinol sodium) for Injection were reported in 19 patients. Fifteen of these adverse experiences were allergic in nature (<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, local <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reaction</span>). One adverse experience of severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and one incidence of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> were also reported as being possibly attributable to ALOPRIM (allopurinol sodium) for Injection. Two patients had serious adverse experiences (decreased renal function and generalized <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>) reported as being possibly attributable to ALOPRIM (allopurinol sodium) for Injection.</p>
<p>A listing of the adverse reactions regardless of causality reported from clinical trials follows:</p>
<table width="100%">
<col width="31%">
<col width="33%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule"><p class="First"><span class="Bold">Incidence Greater Than 1%:</span></p></td>
<td class="Toprule"></td>
</tr>
<tr>
<td><p class="First">Cutaneous/Dermatologic:</p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (1.5%)</p></td>
</tr>
<tr>
<td><p class="First">Genitourinary:</p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>/insufficiency (1.2%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First">Gastrointestinal:</p></td>
<td class="Botrule"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (1.3%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (1.2%)</p></td>
</tr>
</tbody>
</table>
<table width="100%">
<col width="26%">
<col width="74%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule"><p class="First"><span class="Bold">Incidence Less Than 1%:</span></p></td>
<td class="Toprule"></td>
</tr>
<tr>
<td><p class="First">Body as Whole:</p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, enlarged abdomen, <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucositis</span>/<span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, blast crisis, <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span>, <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">hypervolemia</span></p></td>
</tr>
<tr>
<td><p class="First">Cardiovascular:</p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, cardiorespiratory arrest, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolus</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, decreased venous pressure, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="196236" conceptname="Septic shock">septic shock</span>, <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">cardiovascular disorder</span>, ECG abnormality, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span></p></td>
</tr>
<tr>
<td><p class="First">Cutaneous/Dermatologic:</p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, local <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reaction</span></p></td>
</tr>
<tr>
<td><p class="First">Gastrointestinal:</p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>, <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span>, <span class="product-label-link" type="condition" conceptid="200527" conceptname="Splenomegaly">splenomegaly</span>, <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>, <span class="product-label-link" type="condition" conceptid="4215578" conceptname="Proctitis">proctitis</span></p></td>
</tr>
<tr>
<td><p class="First">Genitourinary:</p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, increased creatinine, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, kidney function abnormality, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span></p></td>
</tr>
<tr>
<td><p class="First">Hematologic:</p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, marrow <span class="product-label-link" type="condition" conceptid="4166825" conceptname="Aplasia">aplasia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymosis</span>, bone marrow suppression, <span class="product-label-link" type="condition" conceptid="436093" conceptname="Disseminated intravascular coagulation">disseminated intravascular coagulation</span></p></td>
</tr>
<tr>
<td><p class="First">Metabolic:</p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>, <span class="product-label-link" type="condition" conceptid="4065502" conceptname="Hyperphosphatemia">hyperphosphatemia</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span>, <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte abnormality</span>, <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">hypernatremia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>, <span class="product-label-link" type="condition" conceptid="4215499" conceptname="Water intoxication syndrome">water intoxication</span>, <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span></p></td>
</tr>
<tr>
<td><p class="First">Neurologic:</p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, <span class="product-label-link" type="condition" conceptid="373748" conceptname="Grand mal status">status epilepticus</span>, <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span>, <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="436222" conceptname="Altered mental status">mental status changes</span>, <span class="product-label-link" type="condition" conceptid="443454" conceptname="Cerebral infarction">cerebral infarction</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span></p></td>
</tr>
<tr>
<td><p class="First">Pulmonary:</p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span>/insufficiency, <span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">ARDS</span>, increased respiration rate, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span></p></td>
</tr>
<tr>
<td><p class="First">Musculoskeletal:</p></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span></p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First">Other:</p></td>
<td class="Botrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">hypotonia</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, <span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">tumor lysis syndrome</span></p></td>
</tr>
</tbody>
</table>
<p>The most frequent adverse reaction to oral allopurinol is <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>. <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin reactions</span> can be severe and sometimes fatal. Therefore, treatment with ALOPRIM (allopurinol sodium) for Injection should be discontinued immediately if a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> develops (see <a href="#i4i_warnings_ID_warnings">WARNINGS</a>). For further details on <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> to treatment with oral allopurinol, refer to the package insert for allopurinol tablets.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_6474c241-1058-481e-96c4-b57772868050"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Massive overdosing or acute <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> by ALOPRIM (allopurinol sodium) for Injection has not been reported.</p>
<p>In mice, the minimal lethal dose is 45 mg/kg given intravenously or 500 mg/kg orally (about 1/3 or 4 times the usual human dose on a mg/m<span class="Sup">2</span> basis). <span class="product-label-link" type="condition" conceptid="4139968" conceptname="Underactive">Hypoactivity</span> was observed with these doses. In rats, the minimum lethal dose is 100 mg/kg i.v., and 5000 mg/kg orally (about 1.5 and 75 times the usual human dose on a mg/m<span class="Sup">2</span> basis).</p>
<p>In the management of overdosage, there is no specific antidote for ALOPRIM (allopurinol sodium) for Injection. There has been no clinical experience in the management of a patient who has taken massive amounts of allopurinol.</p>
<p>Both allopurinol and oxypurinol are dialyzable; however, the usefulness of hemodialysis or peritoneal dialysis in the management of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of ALOPRIM (allopurinol sodium) for Injection is unknown.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_ID_da"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5b3c6a96-415e-43a8-8710-62cf0f3c5c44"></a><a name="section-10.1"></a><p></p>
<h2>Children and Adults</h2>
<p class="First">The dosage of ALOPRIM (allopurinol sodium) for Injection to lower serum uric acid to normal or near-normal varies with the severity of the disease. The amount and frequency of dosage for maintaining the serum uric acid just within the normal range is best determined by using the serum uric acid level as an index. In adults, in one clinical trial, doses over 600 mg a day did not appear to be more effective. The recommended daily dose of ALOPRIM (allopurinol sodium) for Injection is as follows:</p>
<table width="100%">
<col width="8%">
<col width="30%">
<thead><tr class="First Last"><th class="Botrule Lrule Rrule Toprule" align="left" colspan="2" valign="top"><span class="Bold">Recommended Daily Dose</span></th></tr></thead>
<tbody>
<tr class="First">
<td class="Lrule Toprule"><p class="First">Adult:</p></td>
<td class="Rrule Toprule"><p class="First">200 to 400 mg/m<span class="Sup">2</span>/day <br>Maximum 600 mg/day</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First">Child:</p></td>
<td class="Botrule Rrule"><p class="First">Starting Dose 200 mg/m<span class="Sup">2</span>/day</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d6dd5df3-84ae-4ed9-b537-9a60bd0b1a08"></a><a name="section-10.2"></a><p></p>
<h2>Hydration</h2>
<p class="First">A fluid intake sufficient to yield a daily urinary output of at least two liters in adults and the maintenance of a neutral or, preferably, slightly alkaline urine are desirable.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_98889c72-45a2-4aa5-9c15-81dc690291fa"></a><a name="section-10.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></h2>
<p class="First">The dose of ALOPRIM (allopurinol sodium) for Injection should be reduced in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> to avoid accumulation of allopurinol and its metabolites:</p>
<table width="100%">
<col width="23%">
<col width="33%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Creatinine Clearance</span></th>
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Recommended Daily Dose</span></th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule Toprule"><p class="First">10 to 20 mL/min</p></td>
<td class="Rrule Toprule"><p class="First">200 mg/day</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First">3 to 10 mL/min</p></td>
<td class="Rrule"><p class="First">100 mg/day</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First">&lt;3 mL/min</p></td>
<td class="Botrule Rrule"><p class="First">100 mg/day at extended intervals</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_be892e8e-36b6-469c-bd5e-5f8ade173f1f"></a><a name="section-10.4"></a><p></p>
<h2>Administration</h2>
<p class="First">In both adults and children, the daily dose can be given as single infusion or in equally divided infusions at 6-, 8-, or 12- hour intervals at the recommended final concentration of not greater than 6 mg/mL (see <a href="#i4i_section_ID_preparation">Preparation of Solution</a>). The rate of infusion depends on the volume of infusate. Whenever possible, therapy with ALOPRIM (allopurinol sodium) for Injection should be initiated 24 to 48 hours before the start of chemotherapy known to cause tumor cell lysis (including adrenocortical steroids).</p>
<p>ALOPRIM (allopurinol sodium) for Injection should not be mixed with or administered through the same intravenous port with agents which are incompatible in solution with ALOPRIM (allopurinol sodium) for Injection (see <a href="#i4i_section_ID_preparation">Preparation of Solution</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_preparation"></a><a name="section-10.5"></a><p></p>
<h2>Preparation of Solution</h2>
<p class="First">ALOPRIM (allopurinol sodium) for Injection must be reconstituted and diluted. The contents of each 30 mL vial should be dissolved with 25 mL of Sterile Water for Injection. Reconstitution yields a clear, almost colorless solution with no more than a slight opalescence. This concentrated solution has a pH of 11.1 to 11.8. It should be diluted to the desired concentration with 0.9% Sodium Chloride Injection or 5% Dextrose for Injection. Sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>-containing solutions should not be used. A final concentration of no greater than 6 mg/mL is recommended. The solution should be stored at 20Â° to 25Â°C (68Â° to 77Â°F) and administration should begin within 10 hours after reconstitution. Do not refrigerate the reconstituted and/or diluted product.</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use this product if particulate matter or discoloration is present.</p>
<p>The following table lists drugs that are physically incompatible in solution with ALOPRIM (allopurinol sodium) for Injection.</p>
<a name="_Refid_d50db969-c9c3-44e7-978d-3574d8f09"></a><table width="100%">
<caption><span>Drugs That Are Physically Incompatible in Solution with ALOPRIM<span class="Sup">Â®</span> (allopurinol sodium) for Injection</span></caption>
<col width="24%">
<col width="37%">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Toprule"><p class="First">Amikacin sulfate</p></td>
<td class="Rrule Toprule"><p class="First">Hydroxyzine HCl</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First">Amphotericin B</p></td>
<td class="Rrule"><p class="First">Idarubicin HCl</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First">Carmustine</p></td>
<td class="Rrule"><p class="First">Imipenem-cilastatin sodium</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First">Cefotaxime sodium</p></td>
<td class="Rrule"><p class="First">Mechlorethamine HCl</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First">Chlorpromazine HCl</p></td>
<td class="Rrule"><p class="First">Meperidine HCl</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First">Cimetidine HCl</p></td>
<td class="Rrule"><p class="First">Metoclopramide HCl</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First">Clindamycin phosphate</p></td>
<td class="Rrule"><p class="First">Methylprednisolone sodium succinate</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First">Cytarabine</p></td>
<td class="Rrule"><p class="First">Minocycline HCl</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First">Dacarbazine</p></td>
<td class="Rrule"><p class="First">Nalbuphine HCl</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First">Daunorubicin HCl</p></td>
<td class="Rrule"><p class="First">Netilmicin sulfate</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First">Diphenhydramine HCl</p></td>
<td class="Rrule"><p class="First">Ondansetron HCl</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First">Doxorubicin HCl</p></td>
<td class="Rrule"><p class="First">Prochlorperazine edisylate</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First">Doxycycline hyclate</p></td>
<td class="Rrule"><p class="First">Promethazine HCl</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First">Droperidol</p></td>
<td class="Rrule"><p class="First">Sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span></p></td>
</tr>
<tr>
<td class="Lrule"><p class="First">Floxuridine</p></td>
<td class="Rrule"><p class="First">Streptozocin</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First">Gentamicin sulfate</p></td>
<td class="Rrule"><p class="First">Tobramycin sulfate</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First">Haloperidol lactate</p></td>
<td class="Botrule Rrule"><p class="First">Vinorelbine tartrate</p></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_590796ee-5803-46ad-b1b9-b188b987915c"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">STERILE SINGLE-USE VIAL FOR INTRAVENOUS INFUSION.</p>
<p>ALOPRIM (allopurinol sodium) for Injection, 30 mL flint glass vials with rubber stoppers each containing allopurinol sodium equivalent to 500 mg of allopurinol (white lyophilized powder).</p>
<p>NDC 67457-187-50<br>carton containing one vial</p>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_7b866da5-e620-4829-b14c-2a084554c790"></a><a name="section-11.1"></a><p></p>
<p class="First">Store unreconstituted powder at <span class="Bold">20Â° to 25Â°C (68Â° to 77Â°F). [See USP Controlled Room Temperature.]</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_21d5b75f-260b-430e-a136-24eacaf71c40"></a><a name="section-12"></a><p></p>
<p class="First">Manufactured for:<br><span class="Bold">Mylan Institutional LLC</span><br>Rockford, IL 61103 U.S.A.</p>
<p>Manufactured by:<br><span class="Bold">Patheon Manufacturing Services LLC</span><br>Greenville, NC 27834</p>
<p>013401<br>REVISED JUNE 2014<br>MI:ALOPIJ:R4</p>
<p>ALOPRIM<span class="Sup">Â®</span> is a registered trademark of Mylan Teoranta.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_e8fd6862-532f-4dea-8509-5bd650ed712d"></a><a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 500 mg Label</h1>
<p class="First"><span class="Bold">NDC 67457-187-50 Â Â Â Â Â 500 mg</span></p>
<p><span class="Bold">ALOPRIM<span class="Sup">Â®</span></span><br><span class="Bold">(allopurinol sodium)</span><br><span class="Bold">for Injection</span><br><span class="Bold">500 mg</span></p>
<p>equivalent to 500 mg <br>allopurinol</p>
<p><span class="Bold">For Intravenous Infusion</span></p>
<p><span class="Bold">Rx only Single-Use Vial</span></p>
<p>Sterile</p>
<p><span class="Bold">Preparation of Solution:</span><br>Inject 25 mL Sterile Water for<br>Injection into vial. Swirl vial until<br>solution results. The solution<br>should be stored at 20Â° to 25Â°C<br>(68Â° to 77Â°F) and administration<br>should begin within 10 hours<br>after reconstitution. Further<br>dilution is required before<br>intravenous administration.</p>
<p><span class="Bold">Usual Dosage and</span><br><span class="Bold">Reconstitution Instructions:</span><br>See accompanying prescribing<br>information.</p>
<p><span class="Bold">Store at 20Â° to 25Â°C (68Â° to</span><br><span class="Bold">77Â°F). [See USP Controlled</span><br><span class="Bold">Room Temperature.]</span></p>
<p>ALOPRIMÂ® is a registered trademark of<br>Mylan Teoranta</p>
<p>Manufactured for:<br><span class="Bold">Mylan Institutional LLC</span><br>Rockford, IL 61103 U.S.A.</p>
<p>Made in U.S.A.</p>
<p>MI:187:1C:R3</p>
<p><span class="Bold">Mylan.com</span></p>
<div class="Figure">
<a name="id924"></a><img alt="ALOPRIM (allopurinol sodium) for Injection 500 mg Carton Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=10cc918f-aa44-415b-932d-2404695ac449&amp;name=084bfc21-a46e-45e5-925d-aaa806351658-02.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ALOPRIMÂ 		
					</strong><br><span class="contentTableReg">allopurinol injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:67457-187</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Allopurinol</strong> (Allopurinol) </td>
<td class="formItem">Allopurinol</td>
<td class="formItem">500Â mg Â inÂ 25Â mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:67457-187-50</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">25 mL in 1 VIAL, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020298</td>
<td class="formItem">05/01/1996</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Mylan Institutional LLC
							(790384502)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 6/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>2459a429-7031-454e-a6ef-144bb4cd1870</div>
<div>Set id: 10cc918f-aa44-415b-932d-2404695ac449</div>
<div>Version: 4</div>
<div>Effective Time: 20140630</div>
</div>
</div>Â <div class="DistributorName">Mylan Institutional LLC</div></p>
</body></html>
